Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab.
Sasaki Y, Matsumoto K, Takaki A, Adachi T, Takahara M, Ozato K, Takeuchi Y, Sue M, Miyake N, Wada N, Onishi H, Shiraha H, Oda T, Tsutsumi K, Nouso K, Kariyama K, Hagihara H, Moriya A, Otsuka M. Sasaki Y, et al. Among authors: nouso k. Gastro Hep Adv. 2024 Aug 2;3(8):1138-1147. doi: 10.1016/j.gastha.2024.07.018. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39559295 Free PMC article.
The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
Takeuchi Y, Nouso K, Fujioka SI, Kariyama K, Kobashi H, Uematsu S, Moriya A, Hagihara H, Takabatake H, Nakamura S, Yabushita K, Kikuchi T, Oyama A, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A. Takeuchi Y, et al. Among authors: nouso k. Cancer Med. 2023 Sep;12(17):17559-17568. doi: 10.1002/cam4.6369. Epub 2023 Aug 3. Cancer Med. 2023. PMID: 37537956 Free PMC article.
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Tada T, Yasunaka T, Sakata M, Sue M, Miyake N, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A, Otsuka M. Kikuchi T, et al. Among authors: nouso k. Liver Int. 2024 Jun;44(6):1456-1463. doi: 10.1111/liv.15907. Epub 2024 Mar 15. Liver Int. 2024. PMID: 38488749
Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma.
Miyahara K, Nouso K, Morimoto Y, Tomoda T, Kobayashi S, Takeuchi Y, Hagihara H, Kuwaki K, Ohnishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K; Okayama Liver Cancer Group. Miyahara K, et al. Among authors: nouso k. Hepatol Res. 2013 Oct;43(10):1064-70. doi: 10.1111/hepr.12055. Epub 2013 Jan 25. Hepatol Res. 2013. PMID: 23347420
Serum oxidative-anti-oxidative stress balance is dysregulated in patients with hepatitis C virus-related hepatocellular carcinoma.
Nishimura M, Takaki A, Tamaki N, Maruyama T, Onishi H, Kobayashi S, Nouso K, Yasunaka T, Koike K, Hagihara H, Kuwaki K, Nakamura S, Ikeda F, Iwasaki Y, Tomofuji T, Morita M, Yamamoto K. Nishimura M, et al. Among authors: nouso k. Hepatol Res. 2013 Oct;43(10):1078-92. doi: 10.1111/hepr.12048. Epub 2013 Jan 30. Hepatol Res. 2013. PMID: 23363268 Free article.
Prognotic impact of serum follistatin in patients with hepatocellular carcinoma.
Tomoda T, Nouso K, Miyahara K, Kobayashi S, Kinugasa H, Toyosawa J, Hagihara H, Kuwaki K, Onishi H, Nakamura S, Ikeda F, Miyake Y, Shiraha H, Takaki A, Yamamoto K. Tomoda T, et al. Among authors: nouso k. J Gastroenterol Hepatol. 2013 Aug;28(8):1391-6. doi: 10.1111/jgh.12167. J Gastroenterol Hepatol. 2013. PMID: 23432377
294 results